Can You Get Pregnant With Granulomatosis With Polyangiitis?
At a Glance
Yes, you can safely get pregnant and have a healthy baby after a Granulomatosis with polyangiitis (GPA) diagnosis. It requires at least six months of disease remission and transitioning to pregnancy-safe medications like azathioprine under the care of a maternal-fetal medicine specialist.
In this answer
3 sections
Yes, it is possible to safely get pregnant and have a healthy baby after being diagnosed with Granulomatosis with polyangiitis (GPA) [1][2]. However, a safe pregnancy requires meticulous planning, a multidisciplinary medical team, and strict medication management [3][4]. Because the heavy immunosuppressant drugs used to treat GPA can affect both your fertility and a developing fetus, pregnancy should only be attempted when your disease is in sustained remission and your medication regimen has been adjusted for safety [3][5].
The Importance of Timing and Remission
The single most critical factor for a safe pregnancy with GPA is ensuring your disease has been in a stable, quiet state—known as remission—for at least 6 months before you attempt to conceive [3][2].
Attempting pregnancy while GPA is active carries significant risks. The disease course can be unpredictable, and active inflammation—especially if it involves your kidneys—can lead to severe maternal and fetal complications, including premature birth or preeclampsia [2][1]. Furthermore, relapses can occur during the pregnancy itself or in the postpartum period, making close monitoring essential [6].
To navigate these risks, your care must be collaborative. You will need both your rheumatologist and a high-risk obstetrician, often called a Maternal-Fetal Medicine (MFM) specialist, working together to monitor your health [1][4].
Will my baby inherit GPA?
GPA is not a classically hereditary disease [7][8]. While there are some genetic predispositions associated with it, the disease is not passed directly from parent to child in a predictable pattern, and the risk to your offspring is considered very low [7][8].
How GPA Treatments Impact Fertility
Some of the most effective medications used to induce remission in GPA can have a lasting impact on your ability to have children, affecting both men and women.
Cyclophosphamide is a powerful immunosuppressant that carries a high risk of causing premature ovarian insufficiency, which can lead to permanent infertility in women [9][10]. For men, cyclophosphamide is associated with adverse impacts on spermatogenesis (sperm production) [11][12]. The risk of fertility damage increases with higher cumulative doses of the drug [5].
Because of these risks, it is crucial for both men and women to discuss fertility preservation—such as freezing eggs (oocyte cryopreservation), embryos, or sperm—with a reproductive specialist before starting cyclophosphamide treatment [13][14].
In many modern treatment plans, rituximab is used as an alternative to cyclophosphamide specifically because it is effective at inducing remission while largely sparing your fertility [15][10].
Medication Safety During Pregnancy
The medications that keep your immune system in check must be carefully reviewed before you attempt to conceive. Many standard GPA treatments are profoundly dangerous to a developing fetus and must be stopped well in advance. If you experience an unplanned pregnancy while taking any of the unsafe medications listed below, contact your doctor immediately.
| Medication Category | Drugs | Pregnancy Safety Guidelines |
|---|---|---|
| Safe During Pregnancy | Azathioprine, Glucocorticoids (Prednisone) | Commonly used to safely maintain remission during pregnancy [1][4]. While safe for the developing baby, glucocorticoids require close monitoring for maternal side effects like gestational diabetes or high blood pressure [1]. Both are generally considered compatible with breastfeeding. |
| Requires Washout Period | Rituximab | Often stopped 6 months before trying to conceive [16]. This waiting period prevents the drug from crossing the placenta and depleting the developing baby’s B-cells (a type of immune cell) [17]. |
| Strictly Avoid (Teratogenic) | Methotrexate, Mycophenolate Mofetil, Cyclophosphamide | Highly teratogenic (known to cause severe birth defects) [5][18]. Must be discontinued prior to conception—typically 1 to 3 months for methotrexate, and at least 6 weeks for mycophenolate mofetil [5][18]. |
(Note on male medication safety: Current evidence is generally reassuring regarding paternal exposure. There is no firm evidence of harm to a pregnancy caused by a father’s use of rituximab, methotrexate, or mycophenolate mofetil [11][12].)
By coordinating closely with your doctors, protecting your fertility early, and ensuring your medications are pregnancy-safe, you can maximize your chances of a healthy pregnancy and a healthy baby.
Common questions in this guide
How long do I need to be in remission before getting pregnant with GPA?
Will cyclophosphamide affect my ability to have children?
Will my baby inherit Granulomatosis with polyangiitis?
Which GPA medications are safe to take during pregnancy?
Do I need a special doctor if I get pregnant with GPA?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current disease activity level, and have I been in stable remission for at least 6 months?
- 2.Do I have any history of kidney involvement that might classify my pregnancy as higher risk?
- 3.What is my cumulative dose of cyclophosphamide, and should we discuss fertility preservation before continuing treatment?
- 4.Which maintenance medication (such as azathioprine) will I transition to before trying to conceive, and what is our target timeline for the switch?
- 5.Can you refer me to a Maternal-Fetal Medicine (MFM) specialist for a pre-conception planning visit?
- 6.How will we monitor for potential GPA relapses during the postpartum period?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (18)
- 1
Favorable Pregnancy Outcome in a Granulomatosis With Polyangiitis Patient With Renal Insufficiency.
Verma A, Rajbhar S, Thakur P, et al.
Journal of medical cases 2021; (12(1)):27-31 doi:10.14740/jmc3610.
PMID: 34434424 - 2
Maternal and fetal outcomes of pregnancy in women with primary systemic vasculitis: A single-center cohort study of 20 patients and 30 pregnancies.
Beça S, Alba MA, Hernández-Rodríguez J, et al.
Seminars in arthritis and rheumatism 2024; (66()):152412 doi:10.1016/j.semarthrit.2024.152412.
PMID: 38387195 - 3
Natural Killer Cells in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - A Review of the Literature.
Fuchs S, Scheffschick A, Gunnarsson I, Brauner H
Frontiers in immunology 2021; (12()):796640 doi:10.3389/fimmu.2021.796640.
PMID: 35116030 - 4
Granulomatosis with polyangiitis in pregnancy - clinical implications and treatment possibilities.
Grygiel-Górniak B, Puszczewicz M
European review for medical and pharmacological sciences 2015; (19(13)):2331-5.
PMID: 26214766 - 5
Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.
King C, Harper L
Current treatment options in rheumatology 2017; (3(4)):230-243 doi:10.1007/s40674-017-0082-y.
PMID: 29201630 - 6
Successful treatment outcomes in pregnant patients with ANCA-associated vasculitides: A systematic review of literature.
Singh P, Dhooria A, Rathi M, et al.
International journal of rheumatic diseases 2018; (21(9)):1734-1740 doi:10.1111/1756-185X.13342.
PMID: 30345645 - 7
Alpha-1 antitrypsin deficiency and granulomatosis with polyangiitis: a systematic review and meta-analysis.
Alluhibi R, Baradwaaj S, Heyer-Chauhan N, et al.
European respiratory review : an official journal of the European Respiratory Society 2025; (34(178)) doi:10.1183/16000617.0088-2025.
PMID: 41125409 - 8
Epidemiology and genetics of granulomatosis with polyangiitis.
Banerjee P, Jain A, Kumar U, Senapati S
Rheumatology international 2021; (41(12)):2069-2089 doi:10.1007/s00296-021-05011-1.
PMID: 34635927 - 9
Pregnancy in patients with systemic lupus erythematosus after cyclophosphamide therapy.
Sen M, Kurl A, Khosroshahi A
Lupus 2021; (30(9)):1509-1514 doi:10.1177/09612033211021163.
PMID: 34053364 - 10
Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
Specks U
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2015; (30(7)):1083-7 doi:10.1093/ndt/gfv217.
PMID: 25999375 - 11
Paternal safety of anti-rheumatic medications.
Bermas BL
Best practice & research. Clinical obstetrics & gynaecology 2020; (64()):77-84 doi:10.1016/j.bpobgyn.2019.09.004.
PMID: 31727565 - 12
Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence.
Mouyis M, Flint JD, Giles IP
Seminars in arthritis and rheumatism 2019; (48(5)):911-920 doi:10.1016/j.semarthrit.2018.07.011.
PMID: 30220537 - 13
Fertility preservation in women with cancer and afterward.
Hunt S, Vollenhoven B
Climacteric : the journal of the International Menopause Society 2019; (22(6)):579-583 doi:10.1080/13697137.2019.1607285.
PMID: 31079511 - 14
The role of gonadotropin-releasing hormone agonists in female fertility preservation.
Lee JH, Choi YS
Clinical and experimental reproductive medicine 2021; (48(1)):11-26 doi:10.5653/cerm.2020.04049.
PMID: 33648041 - 15
Targeted immunotherapy strategies in ANCA-associated vasculitis.
Puéchal X
Joint bone spine 2019; (86(3)):321-326 doi:10.1016/j.jbspin.2018.09.002.
PMID: 30201478 - 16
A comprehensive review of rituximab therapy in rheumatoid arthritis patients.
Tavakolpour S, Alesaeidi S, Darvishi M, et al.
Clinical rheumatology 2019; (38(11)):2977-2994 doi:10.1007/s10067-019-04699-8.
PMID: 31367943 - 17
Rituximab administration during the second trimester of pregnancy for systemic lupus erythematosus: Case report and review of the literature on rheumatic disease.
Colquhoun M, Thanopoulou V, Quick V, Mouyis M
Modern rheumatology case reports 2022; (6(2)):173-177 doi:10.1093/mrcr/rxab051.
PMID: 34850082 - 18
Impact of rheumatoid arthritis and methotrexate on pregnancy outcomes: retrospective cohort study of the Italian Society for Rheumatology.
Zanetti A, Zambon A, Scirè CA, Bortoluzzi A
RMD open 2022; (8(2)) doi:10.1136/rmdopen-2022-002412.
PMID: 36597979
This page provides educational information about family planning and Granulomatosis with polyangiitis (GPA). Always consult your rheumatologist and a maternal-fetal medicine specialist before attempting to conceive or changing your medication regimen.
Get notified when new evidence is published on Granulomatosis with polyangiitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.